Glucocorticoid Immunoablation for Non-Myeloablative Lymphocyte Reset
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases and lymphocyte-mediated conditions, such as Type 1 diabetes and lymphomas, are either ineffective or associated with significant toxicity, high costs, and risks, including chemotherapy and radiation therapies.
Innovation Solution
The use of high doses of glucocorticoids, specifically dexamethasone or betamethasone, to achieve lymphodepletion without affecting other cell types, thereby providing a safer and more effective immunologic reset regimen.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy or radiation therapy is used to deplete lymphocytes, then lymphodepletion is achieved, but severe toxicity and non-selective destruction of other cell types occur
Solution Approach 1:
The patent applies local quality by making the lymphodepletion selective rather than uniform. Glucocorticoids specifically target lymphocytes through their glucocorticoid receptors, which are highly expressed on lymphocyte surfaces, while sparing other cell types that do not express these receptors. This selective mechanism achieves lymphodepletion without the non-selective destruction caused by chemotherapy and radiation.
Solution Approach 2:
The patent utilizes parameter changes by exploiting the specific biochemical parameters of glucocorticoid-receptor interaction. By administering glucocorticoids at controlled doses, the treatment leverages the high affinity binding between glucocorticoids and their receptors on lymphocytes, triggering apoptosis specifically in these cells while maintaining normal function of other cell types with different receptor profiles.
2Reliability
If high doses of glucocorticoids are administered to achieve lymphodepletion, then selective lymphocyte depletion is achieved, but potential side effects from high-dose steroid administration occur
Solution Approach 1:
The patent applies partial or excessive action by administering glucocorticoids at high doses temporarily to achieve complete lymphodepletion, then discontinuing the treatment. This allows the therapeutic effect of maximal lymphocyte depletion to be achieved while limiting the duration of exposure to potential side effects. The transient nature of the treatment minimizes long-term steroid-related adverse effects while achieving the desired immunologic reset.
3Reliability
If conventional immunosuppressive therapy is used for autoimmune diseases, then immune suppression is achieved, but prolonged treatment with significant side effects and relapse risks is required
Solution Approach 1:
The patent applies preliminary action by first depleting the lymphocyte pool with glucocorticoids before the autoimmune response can cause significant damage. This creates a window of opportunity where the immune system is reset, allowing for potential repopulation with tolerant immune cells. This preliminary depletion strategy prevents the need for prolonged continuous immunosuppression, as the initial glucocorticoid pulse achieves the therapeutic effect that would otherwise require months of ongoing treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The high-dose glucocorticoids effectively deplete peripheral blood lymphocytes, reduce germinal centers, and minimize relapse risks, offering a non-myeloablative treatment that is safer and less costly than existing therapies, with rapid recovery and reduced hospitalization needs.
Implementation Method 1
high dose glucocorticoids also lymphodeplete peripheral blood lymphocytes via a biologic mechanism (in contrast to the cytotoxic mechanism underpinning preconditioning with chemotherapeutic agents or radiotherapy)
Implementation Method 2
high dose glucocorticoids can cause ablation of lymphoid tissues to reduce the binding of cellular immunotherapies to lymphoid tissue, in particular to germinal centers and marginal zones in lymph nodes and germinal centers and marginal zones in the spleen
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This invention pertains to pharmaceutical compositions comprising a glucocorticoid for use in the treatment of diseases by immunoablation. The compositions of the invention may be for use in the treatment of diseases that are mediated by immune cells such as lymphocytes.